MacroGenics Terminates Henlius Biotech Deal

Ticker: MGNX · Form: 8-K · Filed: 2024-09-16T00:00:00.000Z

Sentiment: neutral

Topics: collaboration-termination, licensing-agreement, drug-development

Related Tickers: HENLF

TL;DR

MGNX just dumped its Henlius deal for Margetuximab, effective immediately.

AI Summary

On September 16, 2024, MacroGenics, Inc. (MGNX) filed an 8-K report to announce the termination of its collaboration and license agreement with Shanghai Henlius Biotech, Inc. for the development and commercialization of the drug candidate HLX10 (also known as Margetuximab). This termination is effective immediately.

Why It Matters

The termination of this collaboration impacts the future development and commercialization strategy for Margetuximab, potentially affecting MacroGenics' revenue streams and pipeline.

Risk Assessment

Risk Level: medium — The termination of a significant collaboration agreement can introduce uncertainty regarding future revenue and development timelines.

Key Players & Entities

FAQ

What is the primary reason for the termination of the collaboration and license agreement?

The filing does not explicitly state the reason for termination, only that it has occurred.

What is the effective date of the termination?

The termination is effective immediately as of September 16, 2024.

What drug candidate was covered by the terminated agreement?

The drug candidate covered was HLX10, also known as Margetuximab.

Which companies were involved in the terminated agreement?

MacroGenics, Inc. and Shanghai Henlius Biotech, Inc. were involved.

What is the trading symbol for MacroGenics, Inc. common stock?

The trading symbol for MacroGenics, Inc. common stock is MGNX.

Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-09-16 16:02:02

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On September 15, 2024, MacroGenics, Inc. (the "Company") issued a press release announcing updated efficacy and safety data related to its Phase 2 TAMARACK clinical trial of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (the "Press Release"). The Company included the updated efficacy and safety data in a poster presentation at the European Society for Medical Oncology ("ESMO") Congress, taking place in Barcelona, Spain from September 13-17, 2024. As announced in the Press Release, the Company also hosted an investor conference call on September 16, 2024 in which the Company presented a review of the TAMARACK Phase 2 data and also provided a general corporate update (the "Post-ESMO Conference Call Presentation"). The full text of the Press Release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. In addition, a copy of the Post-ESMO Conference Call Presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release , dated September 1 5 , 2024 . 99.2 Post-ESMO Conference Call Presentation. 104 Cover Page Interactive Data File (formatted as Inline XBRL). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 16, 2024 MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel

View on Read The Filing